Brainomix receives funding to develop clinical decision-making software for stroke patients Monday 10 August 2015 PDF Print We are now able to develop software that will empower physicians to identify stroke patients who benefit from the life-saving, but expensive treatment Oxford, UK: Brainomix Limited, a developer of automated medical imaging software for neurological and cerebrovascular disorders, has been awarded £633,553 by the Biomedical Catalyst, a joint programme run by the Medical Research Council (MRC) and Innovate UK. The funding is for two years and will support the development and validation of clinical decision-making support software designed to identify stroke patients who can benefit from mechanical reopening of a brain artery. “We are very honoured to receive this award. We are now able to develop software that will empower physicians to identify stroke patients who benefit from the life-saving, but expensive treatment of mechanical clot removal,” said Dr Michalis Papadakis, Brainomix Chief Executive Officer. The technology, called perfusion-ASPECTS, will automate the procedure to measure tissue at risk on brain CT scans and identify patients who can benefit from mechanical reopening of a brain artery. Worldwide, annually, 13,000,000 people suffer a stroke. Recent studies show that mechanical clot removal improves patient outcome and the procedure is currently transforming stroke treatment. Patient selection is crucial for the adoption of this procedure because it costs up to £23,000 per patient. Brainomix will build on its e-ASPECTS stroke damage measurement software to develop and validate perfusion-ASPECTS. The international reputation of the Brainomix founders in stroke will aid the successful development and clinical adoption of perfusion-ASPECTS. Media contact Dr Michalis Papadakis +44 (0) 1865 582731 email@example.com This press release was distributed by ResponseSource Press Release Wire on behalf of Brainomix in the following categories: Health, Medical & Pharmaceutical, for more information visit http://pressreleasewire.responsesource.com/about.